ScienceDaily PharmaceuticalsOriginal article
Colon cancer breakthrough keeps patients cancer-free for nearly 3 years
Data ReadoutpositivePembrolizumabPositive
AI Analysis
Summary
A UK-led clinical trial demonstrated that nine weeks of pembrolizumab prior to surgery kept colorectal cancer patients cancer-free for nearly three years, challenging the standard post-surgery chemotherapy approach.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
UK-led trial showed patients receiving nine weeks of pembrolizumab prior to surgery remained cancer-free nearly three years later
Importance:7/10
Sentiment:
0.85
immunotherapycolorectal cancerpembrolizumabclinical trialsurgeryUK-led trial
Related Companies
Read the original article
Published by ScienceDaily Pharmaceuticals on May 6, 2026 6:20 AM